Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5 -- Ignore unavailable to you. Want to Upgrade?

To: GARY P GROBBEL who wrote (20756)	5/19/2004 3:18:56 PM
From: Findit	Read Replies (2) \| Respond to of 120415

Gary DOR is being helped by passage of Project BioShield. DOR BioPharma, Inc. is a development-stage biopharmaceutical company specializing in the clinical testing of products that meet unmet medical needs. Through its Biodefense Division, DOR is developing vaccines against ricin toxin and botulinum toxin. DOR's lead therapeutic product, orBec (oral beclomethasone dipropionate), is in a Phase III clinical trial for the treatment of intestinal graft-versus-host disease